

URGENT
PRESS RELEASE



Wockhardt's Q2 Net Profit Crosses the Rs. 100 Crore Mark

*Consolidated Sales rise by 53% at Rs. 630 Crores
Net Profits increase by 62% at Rs. 102 Crores*

Mumbai, July 25, 2007

Pharmaceutical and biotechnology major Wockhardt Limited reported a 62% increase in net profits at Rs. 102 crores for the second quarter ended June 30, 2007. Operating profits climbed 70% to Rs. 152 crores. Operating margins at 24.2% showed an improvement of 250 basis points. Consolidated Sales stood at Rs. 630 crores, showing a 53% growth over the corresponding quarter of 2006.

“With strategic focus, Wockhardt has emerged as the largest Indian Pharmaceutical Company in Europe”, said Wockhardt Chairman Habil Khorakiwala. “We now have presence in the top three markets in Europe, namely UK, France and Germany. Our European business today constitutes over 50% of Wockhardt sales. Another important feature is that India branded business has shown an excellent growth of 25%”.

India

India business continued to show a healthy growth trend outperforming the industry growth rate of 12% in 2007. Wepox (recombinant erythropoietin) is the No. 1 brand in its segment. Four new products were launched in the marketplace, of which, two were in-licensed patented dermatology products – Vitix and Viticolor. Wockhardt's aggressive in-licensing strategy set in motion 12 product deals with a strong emphasis in dermatology.

Europe

Europe continues to be Wockhardt's single largest market accounting for 56% of consolidated sales. 13 new products were launched in the first half of 2007.

USA

The US formulation business grew by 51% in Q2 of 2007 driven by four product launches in the quarter. The USFDA approved Terbinafine tablets was a 'Day-one' launch in the US market during the same period. Wockhardt USA Inc. now markets 21 products.

Wockhardt Limited is a global pharmaceutical and biotechnology major with an innovative research and development programme. Wockhardt has global footprints including UK, France, Germany, Ireland and USA. Wockhardt employs 5500 people worldwide belonging to 14 different nationalities.

WOCKHARDT LIMITED
CONSOLIDATED UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 30TH JUNE, 2007



(RS IN MILLION)

PARTICULARS	Quarter Ended 30/06/2007	% To Sales	Quarter Ended 30/06/2006	% To Sales	Growth%	Half Year Ended 30/06/2007	% To Sales	Half Year Ended 30/06/2006	% To Sales	Growth%	Year Ended 31/12/2006	% To Sales
Income from operations	6,303	100.0	4,127	100.0	52.7	11,531	100.0	7,637	100.0	51.0	17,290	100.0
Total Expenditure	4,781	75.8	3,230	78.3	48.0	8,850	76.7	6,051	79.2	46.3	13,287	76.8
a) (Increase)/Decrease in stock	(527)	(8.4)	44	1.1	(1297.7)	(672)	(5.8)	(278)	(3.6)	(141.7)	(613)	(3.5)
b) Consumption of raw material	1508	23.9	949	23.0	58.9	3,053	26.5	2,008	26.3	52.0	5,085	29.4
c) Purchase of Finished Goods	1325	21.0	579	14.0	128.8	1,975	17.1	1,128	14.8	75.1	2,206	12.8
Material Consumption	2,306	36.6	1,572	38.1	46.7	4,356	37.8	2,858	37.4	52.4	6,678	38.6
d) Staff Cost	1063	16.9	563	13.6	88.8	1874	16.3	1115	14.6	68.1	2,532	14.6
e) R & D Expenditure	140	2.2	273	6.6	(48.7)	300	2.6	502	6.6	(40.2)	610	3.5
f) Other expenditure	1272	20.2	822	19.9	54.7	2,320	20.1	1,576	20.6	47.2	3,467	20.1
Other Expenditure	2,475	39.3	1,658	40.2	49.3	4,494	39.0	3,193	41.8	40.7	6,609	38.2
Gross Profit before Interest, Depreciation & Taxation	1522	24.2	897	21.7	69.7	2,681	23.3	1,586	20.8	69.1	4,003	23.2
Financing Cost (Net)	85	1.3	(6)	(0.1)	(1516.7)	214	1.9	(84)	(1.1)	(354.8)	26	0.2
Gross Profit after Interest but before Depreciation & Taxation	1437	22.8	903	21.9	59.2	2,467	21.4	1,670	21.9	47.7	3,977	23.0
Depreciation	172	2.7	140	3.4	22.9	353	3.1	277	3.6	27.4	621	3.6
Profit after Interest & depreciation	1265	20.1	763	18.5	65.8	2,114	18.3	1,393	18.2	51.8	3,356	19.4
Other Income	25	-	18	-	-	47	-	51	-	-	190	-
Exceptional Items								604			604	
Profit before Tax	1290	20.5	781	18.9	65.2	2,161	18.7	840	11.0	157.3	2,942	17.0
Provision for Taxation												
Current Tax	177	2.8	116	2.8	52.6	301	2.6	162	2.1	85.8	435	2.5
MAT Credit Entitlement											(199)	(1.2)
Fringe Benefit Tax	9	0.1	10	0.2	(10.0)	18	0.2	17	0.2	5.9	33	0.2
Deferred Taxation	80	1.3	21	0.5	281.0	155	1.3	63	0.8	(146.0)	260	1.5
Profit After Tax	1024	16.3	634	15.4	61.6	1687	14.6	598	7.8	182.2	2,413	14.0
Paid-up Equity Share Capital (Rs.5/-each)	547		547			547		547			547	
Reserves excluding Revaluation Reserve (as per last audited Balance-Sheet)	-		-			-		-			10,116	
Basic Earning Per Share (Rs)	9.35		5.80		61.3	15.42		5.47		181.8	22.05	
Diluted Earning Per Share (Rs)	9.35		5.80		61.2	15.41		5.46		182.3	22.04	
Aggregate of Public Shareholding												
- Number of Shares	-		-			2,88,50,521		2,88,40,519			2,88,50,521	
- Percentage to Paid-up Capital	-		-			26.36%		26.36%			26.36%	